NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
+3.84%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$407M
AUM Growth
+$407M
(+43%)
Cap. Flow
+$118M
Cap. Flow
% of AUM
29.08%
Top 10 Holdings %
Top 10 Hldgs %
51.73%
Holding
58
New
21
Increased
11
Reduced
4
Closed
15
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$21.7M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$19M |
| 3 |
Corcept Therapeutics
CORT
|
$17.2M |
| 4 |
AstraZeneca
AZN
|
$16.9M |
| 5 |
Pacira BioSciences
PCRX
|
$14.9M |
Top Sells
| 1 |
Merck
MRK
|
$19.5M |
| 2 |
ABLX
Ablynx NV American Depositary Shares
ABLX
|
$15.9M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$11M |
| 4 |
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
|
$9.16M |
| 5 |
Viatris
VTRS
|
$8.62M |
Sector Composition
| 1 | Healthcare | 93.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $41.8M | 6.89% | 248,620 +40,749 | +20% | +$6.86M |
|
|
2
Bristol-Myers Squibb
BMY
$96B
| $21.7M | 3.57% | +342,399 | New | +$21.7M |
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $21M | 3.46% | 259,235 +95,238 | +58% | +$7.72M |
|
|
SHPG
4
DELISTED
Shire pic
SHPG
| $20.8M | 3.43% | 139,543 -22,406 | -14% | -$3.35M |
|
5
Insmed
INSM
$28.8B
| $20.7M | 3.41% | 918,523 +419,602 | +84% | +$9.45M |
|
|
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
| $19M | 3.13% | +362,974 | New | +$19M |
|
|
7
Corcept Therapeutics
CORT
$7.35B
| $17.2M | 2.83% | +1,045,196 | New | +$17.2M |
|
|
8
AstraZeneca
AZN
$248B
| $16.9M | 2.79% | +484,000 | New | +$16.9M |
|
|
IMMU
9
DELISTED
Immunomedics Inc
IMMU
| $15.8M | 2.6% | 1,081,410 +676,882 | +167% | +$9.89M |
|
|
DOVA
10
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $15.4M | 2.54% | 568,243 +115,211 | +25% | +$3.12M |
|
|
GBT
11
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $15.2M | 2.51% | 315,147 +3,631 | +1% | +$175K |
|
12
Sangamo Therapeutics
SGMO
$157M
| $14.9M | 2.46% | 786,376 +77,832 | +11% | +$1.48M |
|
|
13
Pacira BioSciences
PCRX
$1.2B
| $14.9M | 2.46% | +478,620 | New | +$14.9M |
|
14
Gyre Therapeutics
GYRE
$703M
| $13.9M | 2.29% | 538,624 +227,449 | +73% | +$5.87M |
|
|
SAGE
15
DELISTED
Sage Therapeutics
SAGE
| $12.6M | 2.07% | 78,227 +22,393 | +40% | +$3.61M |
|
16
Heron Therapeutics
HRTX
$207M
| $11.3M | 1.86% | +409,000 | New | +$11.3M |
|
|
CBAY
17
DELISTED
Cymabay Therapeutics
CBAY
| $11.1M | 1.82% | 852,686 +316,118 | +59% | +$4.11M |
|
|
18
Viatris
VTRS
$12.3B
| $10.7M | 1.77% | 261,000 -209,296 | -45% | -$8.62M |
|
|
CLLS
19
Cellectis
CLLS
$258M
| $10.5M | 1.73% | +332,754 | New | +$10.5M |
|
|
AKRX
20
DELISTED
Akorn, Inc.
AKRX
| $9.44M | 1.55% | +504,503 | New | +$9.44M |
|
21
Arrowhead Research
ARWR
$3.05B
| $8.03M | 1.32% | +1,114,097 | New | +$8.03M |
|
|
STML
22
DELISTED
Stemline Therapeutics, Inc.
STML
| $8.01M | 1.32% | +523,624 | New | +$8.01M |
|
23
FibroGen
FGEN
$47.8M
| $6.97M | 1.15% | 150,888 -49,953 | -25% | -$2.31M |
|
24
Kura Oncology
KURA
$686M
| $6.6M | 1.09% | 351,955 -93,595 | -21% | -$1.75M |
|
25
Sol-Gel Technologies
SLGL
$63.5M
| $5.33M | 0.88% | +517,873 | New | +$5.33M |
|